Parkinson’s disease is a chronic and progressive condition affecting the brain and nervous system. It impacts millions of ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Oct. 30, 2024 — The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Nilotinib, a drug approved by the US Food and Drug Administration ... and the International Parkinson and Movement Disorder ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

About 7 million Americans live with chronic neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral ...

It is estimated that around 274,000 people in France suffer from Parkinson’s disease. The vast majority of them follow a treatment of dopaminergic drugs to compensate for their lack of the ...

Favorable capital market conditions last week enabled the company to raise over $15 million from secondary offerings, and the proceeds allow the Company to fund fully the costs of this upcoming ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing ... have long-term complications from treatment Men who undergo prostate cancer ...

Some Diabetes Drugs Tied to Lower Risk of Dementia ... Researchers Target Neurogenesis in New Approach to Treat Parkinson's Disease Apr. 30, 2024 — Researchers have found a way to better ...